QQQ   291.68 (-1.55%)
AAPL   143.62 (-1.58%)
MSFT   243.13 (-2.03%)
META   148.19 (-2.34%)
GOOGL   97.23 (-2.15%)
AMZN   100.85 (-1.36%)
TSLA   172.64 (-2.96%)
NVDA   194.57 (-4.46%)
NIO   12.07 (-5.04%)
BABA   111.92 (-5.46%)
AMD   73.46 (-2.57%)
T   20.08 (+0.65%)
MU   62.01 (-2.91%)
F   13.02 (-1.88%)
CGC   2.89 (-1.37%)
GE   81.77 (-1.75%)
DIS   108.43 (-1.01%)
AMC   5.02 (-8.89%)
PFE   43.68 (-0.25%)
PYPL   80.69 (-1.39%)
NFLX   356.36 (-1.22%)
QQQ   291.68 (-1.55%)
AAPL   143.62 (-1.58%)
MSFT   243.13 (-2.03%)
META   148.19 (-2.34%)
GOOGL   97.23 (-2.15%)
AMZN   100.85 (-1.36%)
TSLA   172.64 (-2.96%)
NVDA   194.57 (-4.46%)
NIO   12.07 (-5.04%)
BABA   111.92 (-5.46%)
AMD   73.46 (-2.57%)
T   20.08 (+0.65%)
MU   62.01 (-2.91%)
F   13.02 (-1.88%)
CGC   2.89 (-1.37%)
GE   81.77 (-1.75%)
DIS   108.43 (-1.01%)
AMC   5.02 (-8.89%)
PFE   43.68 (-0.25%)
PYPL   80.69 (-1.39%)
NFLX   356.36 (-1.22%)
QQQ   291.68 (-1.55%)
AAPL   143.62 (-1.58%)
MSFT   243.13 (-2.03%)
META   148.19 (-2.34%)
GOOGL   97.23 (-2.15%)
AMZN   100.85 (-1.36%)
TSLA   172.64 (-2.96%)
NVDA   194.57 (-4.46%)
NIO   12.07 (-5.04%)
BABA   111.92 (-5.46%)
AMD   73.46 (-2.57%)
T   20.08 (+0.65%)
MU   62.01 (-2.91%)
F   13.02 (-1.88%)
CGC   2.89 (-1.37%)
GE   81.77 (-1.75%)
DIS   108.43 (-1.01%)
AMC   5.02 (-8.89%)
PFE   43.68 (-0.25%)
PYPL   80.69 (-1.39%)
NFLX   356.36 (-1.22%)
QQQ   291.68 (-1.55%)
AAPL   143.62 (-1.58%)
MSFT   243.13 (-2.03%)
META   148.19 (-2.34%)
GOOGL   97.23 (-2.15%)
AMZN   100.85 (-1.36%)
TSLA   172.64 (-2.96%)
NVDA   194.57 (-4.46%)
NIO   12.07 (-5.04%)
BABA   111.92 (-5.46%)
AMD   73.46 (-2.57%)
T   20.08 (+0.65%)
MU   62.01 (-2.91%)
F   13.02 (-1.88%)
CGC   2.89 (-1.37%)
GE   81.77 (-1.75%)
DIS   108.43 (-1.01%)
AMC   5.02 (-8.89%)
PFE   43.68 (-0.25%)
PYPL   80.69 (-1.39%)
NFLX   356.36 (-1.22%)
NYSE:CTLT

Catalent - CTLT Stock Forecast, Price & News

$53.22
-0.43 (-0.80%)
(As of 01/30/2023 01:05 PM ET)
Add
Compare
Today's Range
$52.72
$54.35
50-Day Range
$41.39
$53.65
52-Week Range
$40.69
$115.33
Volume
1.66 million shs
Average Volume
2.55 million shs
Market Capitalization
$9.58 billion
P/E Ratio
22.74
Dividend Yield
N/A
Price Target
$92.40

Catalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
73.8% Upside
$92.40 Price Target
Short Interest
Healthy
3.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.44mentions of Catalent in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$233,414 Sold Last Quarter
Proj. Earnings Growth
13.95%
From $2.94 to $3.35 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.05 out of 5 stars

Medical Sector

12th out of 1,049 stocks

Pharmaceutical Preparations Industry

5th out of 514 stocks


CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

Analysts Set Catalent, Inc. (NYSE:CTLT) PT at $92.40
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Ricky Hopson Sells 643 Shares of Catalent, Inc. (NYSE:CTLT) Stock
Catalent (NYSE:CTLT) Shares Down 4.1% After Analyst Downgrade
Catalent (NYSE:CTLT) Given New $58.00 Price Target at Barclays
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Catalent, Inc. (NYSE:CTLT) Sees Large Increase in Short Interest
Reasons for the Decline of Catalent (CTLT) Stock
Will Catalent (CTLT) Stock Bounce Back?
Catalent Announces Changes to its Board of Directors
Catalent (CTLT) Expands Facility Capabilities in Shanghai
Bear Of The Day: Catalent (CTLT)
Why Shares of Catalent Fell 36% This Week
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
11/01/2022
Today
1/30/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$92.40
High Stock Price Forecast
$145.00
Low Stock Price Forecast
$58.00
Forecasted Upside/Downside
+73.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$503 million
Pretax Margin
10.47%

Debt

Sales & Book Value

Annual Sales
$4.83 billion
Cash Flow
$5.78 per share
Book Value
$26.76 per share

Miscellaneous

Free Float
178,920,000
Market Cap
$9.58 billion
Optionable
Optionable
Beta
1.24

Key Executives

  • Mr. John R. ChiminskiMr. John R. Chiminski (Age 59)
    Exec. Chair of the Board
    Comp: $3.11M
  • Mr. Alessandro  MaselliMr. Alessandro Maselli (Age 51)
    CEO & Director
    Comp: $1.53M
  • Mr. Thomas P. CastellanoMr. Thomas P. Castellano (Age 43)
    Sr. VP & CFO
    Comp: $1.07M
  • Mr. Steven L. Fasman Esq.Mr. Steven L. Fasman Esq. (Age 60)
    Exec. VP, Corp. Sec. & Chief Admin. Officer
    Comp: $1.3M
  • Dr. Aristippos  Gennadios Ph.D.Dr. Aristippos Gennadios Ph.D. (Age 57)
    Group Pres of Pharma & Consumer Health Segment
    Comp: $1.13M
  • Mr. Ricky Hopson (Age 47)
    Pres & Division Head for Clinical Devel. and Supply
  • Ms. Karen Murphy Santiago (Age 52)
    VP & Chief Accounting Office
  • Mr. Julien Meissonnier
    VP & Chief Scientific Officer
  • Mr. Charles Lickfold (Age 49)
    Sr. VP & Chief Information Officer
  • Mr. Paul Surdez
    VP of Investor Relations













CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTLT shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price forecast for 2023?

8 Wall Street analysts have issued 1 year price targets for Catalent's stock. Their CTLT share price forecasts range from $58.00 to $145.00. On average, they predict the company's stock price to reach $92.40 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2023?

Catalent's stock was trading at $45.01 at the beginning of 2023. Since then, CTLT stock has increased by 19.2% and is now trading at $53.65.
View the best growth stocks for 2023 here
.

Are investors shorting Catalent?

Catalent saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 5,940,000 shares, an increase of 17.2% from the December 15th total of 5,070,000 shares. Based on an average daily volume of 3,140,000 shares, the short-interest ratio is presently 1.9 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our CTLT earnings forecast
.

How can I listen to Catalent's earnings call?

Catalent will be holding an earnings conference call on Tuesday, February 7th at 8:15 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) posted its quarterly earnings results on Tuesday, November, 1st. The company reported $0.25 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by $0.24. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a net margin of 8.83% and a trailing twelve-month return on equity of 12.55%.
Read the conference call transcript
.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2023 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of $3.13-$3.54 for the period, compared to the consensus EPS estimate of $3.76. The company issued revenue guidance of $4.63 billion-$4.88 billion, compared to the consensus revenue estimate of $5.08 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Norris Perne & French LLP MI (0.14%), Comerica Bank (0.13%), Mountain Pacific Investment Advisers Inc. ID (0.11%), Vigilant Capital Management LLC (0.07%), Allspring Global Investments Holdings LLC (0.06%) and MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH (0.06%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $53.65.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $9.65 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.34 on an earnings per share basis.

How many employees does Catalent have?

The company employs 19,000 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 1/30/2023 by MarketBeat.com Staff